Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) gapped up before the market opened on Monday. The stock had previously closed at $3.80, but opened at $4.1650. Raia Drogasil shares last traded at $4.1650, with a volume of 2,465 shares trading hands.
Analyst Ratings Changes
Separately, Jefferies Financial Group upgraded Raia Drogasil to a “buy” rating and set a $5.20 price objective for the company in a report on Sunday. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.20.
Read Our Latest Stock Report on RADLY
Raia Drogasil Stock Up 2.8%
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.05. Raia Drogasil had a net margin of 2.99% and a return on equity of 20.12%. The firm had revenue of $2.17 billion for the quarter, compared to analysts’ expectations of $2.32 billion. Research analysts expect that Raia Drogasil S.A. will post 0.17 EPS for the current year.
About Raia Drogasil
Raia Drogasil, now operating under the name RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a network of pharmacies offering prescription medicines, over-the-counter drugs, vitamins, personal care products, beauty items and other health-related merchandise.
The company also provides digital purchasing and delivery services through its online channels, supporting customers with prescription fulfillment, health products and related services. Its operations include pharmacy-based healthcare initiatives designed to complement its retail business and improve access to everyday healthcare.
RD Saúde was created in 2011 through the merger of Drogasil and Droga Raia, two established Brazilian pharmacy chains.
See Also
- Five stocks we like better than Raia Drogasil
- 3M’s Legal Troubles Are Fading. Is the Best Part of Its Rally Still Ahead?
- The AI Buildout Is Only 15% Complete—Here Is Where the Next Dollar Actually Goes
- Cleared For Takeoff: Boeing’s 737 MAX 10 Approval Sets Up a Major Cash Flow Recovery
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
